Now showing items 1-1 of 1

  • Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada 

    Lordkipanidzé, Marie; Marquis-Gravel, Guillaume; Tanguay, Jean-Francois; Mehta, Shamir R.; So, Derek Y. F. (Elsevier, 2020-12-16)
    Background The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary ...